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extraordinarily ow plasma ANP concentration. In gen- 
eral, the plasma ANP concentration shows a graded rise in 
patients with congestive heart failure because atrial dis- 
tention is a key trigger that stimulates ANP secretion. 2 
This patient underwent closed and open mitral commis- 
surotomy more than 30 years ago, at which time the 
appendages must have been removed or ligated. We 
previously reported that the secretory function of ANP 
was impaired after resection of atrial appendages in 
experimental heart failure models. 3 In addition, sustained 
mitral stenosis and tricuspid regurgitation i duced exces- 
sive extension of the atria, which may have further dimin- 
ished the granules producing ANP. Thus it is considered 
that the patient had a lack of ANP secretion despite 
congestive heart failure. 
Infusion of alpha-ANP was notably effective in this 
patient in terms of diuresis and in reducing preload level. 
Saito and associates t first reported the beneficial effect of 
ANP administration i  patients with congestive heart 
failure. We also reported the hemodynamic effects of 
ANP infusion after cardiac operation as cardiac output 
increased and pulmonary arterial pressure decreased. 4 
We recently performed a trial of continuous infusion of 
ANP for more than 24 hours in more than 10 patients 
after cardiac operation irrespective of the plasma ANP 
concentration. In selected patients, ANP infusion mark- 
edly increased urine volume whereas in these patients the 
diuretic effect of furosemide was minimal (unpublished 
data). Continuous infusion of alpha-ANP should be tried 
in patients after cardiac operations when oliguria devel- 
ops. 
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PYODERMA GANGRENOSUM AND MYELOFIBROSIS AFTER CORONARY ARTERY BYPASS 
GRAFTING 
Louis E. Samuels, MD, ~ Marla S. Kaufman, BA, ~ William G. Kussmaul, MD, b and Stanley K. Brockman, MD, a 
Philadelphia, Pa. 
A 66-year-old white man was admitted to the Allegheny 
University Hospitals, Hahnemann Division, Philadelphia, 
in April 1996 with unstable angina and shortness of 
breath. The medical history was significant for coronary 
artery disease, chronic renal failure, and hypertension. On 
admission to the hospital, the white blood cell count was 
8100 per microliter, hemoglobin and hematocrit levels 
were 8.5 gm/dl and 25.1%, and platelet count was 230 
K/UL. Cardiac catheterization 2 days after hospital ad- 
mission showed severe triple-vessel coronary artery dis- 
From the Department of Cardiothoracic Surgery a and the De- 
partment of Medicine, Division of Cardiology, b Allegheny 
University Hospitals, Hahnemann Division, Philadelphia, Pa. 
Received for publication August 26, 1996; accepted for publica- 
tion Sept. 24, 1996. 
Address for reprints: Louis E. Samuels, MD, Allegheny Univer- 
sity Hospitals, Hahnemann Division, Broad and Vine Sts., MS 
111, Philadelphia, PA 19102-1192. 
J Thorac Cardiovasc Surg 1997;113:795-7 
Copyright © 1997 by Mosby-Year Book, Inc. 
0022-5223/97 $5.00 + 0 12/54/78177 
ease. Seven days after hospital admission, the patient 
underwent coronary artery bypass grafting. The immedi- 
ate postoperative course was uneventful. 
On postoperative day (POD) 3, fever (101.7 ° F) and 
sternal tenderness with serous drainage developed. The 
white blood cell count was 15 K/UL. Empiric broad-spec- 
trum antibiotic therapy was started. On POD 5, sternal 
wound debridement was done. No signs of gross infection 
were observed. Instead, there was extensive sternal and 
subcutaneous ti sue necrosis. The operative Gram stain test 
showed negative results for organisms and there was no 
growth on culture. Skin and subcutaneous tissue necrosis 
progressed. On POD 6, an abrupt drop in the white blood 
cell and platelet counts occurred (Figs. 1 and 2). Fever and 
pancytopenia persisted over the next couple of days. 
On POD 13, further sternal wound debridement was 
done. Similar findings of necrotic uninfected tissue 
were observed. On POD 19, histopathologic examina- 
tion of the skin specimens was diagnostic of pyoderma 
gangrenosum. Steroid therapy (hydrocortisone 100 mg 
intravenously every 8 hours) was instituted. On POD 
28, the patient underwent a bone marrow biopsy. 
Myelofibrosis was found. Therapy with bone marrow 
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1 May, 1996 :three-vessel coronary artery bypass grafting 
6 May, 1996: initial wound ebridement 
12 May, 1996: institution of filgrastim (Neupogen) 
14 May, 1996: further wound ebridement 
16 May, 1996: institution of sargramostim (GM-CSF*) 
20 May, 1996: steroid therapy initiated, diagnosis of PG 
29 May, 1996: bone marrow biopsy, diagnosis ofmyelofibrosis 
7 June, 1996: final debridement, s ernal reconstruction 
12 July, t996: discharge 
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Fig. 1. White blood cell count (WBC). GM-CSF, Granulocyte-macrophage colony stimulating factor; PG, 
pyoderma gangrenosum. 
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Fig. 2. Platelet count. GM-CSF, Granulocyte-macrophage colony stimulating factor; PG, pyoderma 
gangrenosum. 
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stimulants was started (filgrastim, 480/xg intravenously, 
and sargramostim, 500/xg intravenous piggyback every 
12 hours). On POD 37, further debridement and recon- 
struction of the sternum with omental transfer and 
split-thickness skin grafting were done. 
The remainder of the hospital course was marked by 
extensive surgical wound care, steroid therapy, intermit- 
tent dialysis, chemical bone marrow stimulation, nutri- 
tional support, and physical rehabilitation. The patient 
was transferred to a rehabilitation center on POD 72. At 
hospital discharge, the white blood cell count was 9.6 
K/UL, hemoglobin and hematocrit values were 7.0 gm/dl 
and 21.6%, and platelet count was 15 K/UL. 
Discussion. Pyoderma gangrenosum is a rare disorder 
and only two case reports document the disease after coro- 
nary artery bypass grafting procedures. 1'2 The cause of 
pyoderma gangrenosum is unknown. It is, however, immu- 
nologic in nature. 3 Characteristically, the lesions are found 
after an injury to the skin. 2 There are no organisms found on 
Gram stain tests and there is no growth on culture. Typically, 
there are ulcerations marked by well-defined borders with a 
blue outline indicating necrosis of the subcutaneous ti sue. 
Although the diagnosis of pyoderma gangrenosum is clinical, 
there are characteristic histopathologic features: acute and 
chronic inflammatory changes, endothelial proliferation, loss 
of the epidermis at the ulcerated sites, and epidermal 
hyperplasia at the borders. 
In our case and in another previously described, 4 pyo- 
derma gangrenosum was linked to  myeloproliferative 
disease. In the report of Romano and Safai, 4 the patient 
was known to have chronic myelocytic leukemia. In that 
case, the skin lesions responded to a course of oral 
prednisone beginning with 80 mg per day. 4 In our case, the 
disease was discovered uring the evaluation of pancyto- 
penia. This delay in diagnosis resulted in further skin and 
subcutaneous necrosis that necessitated extensive de- 
bridement. Once the diagnosis was made, steroid therapy 
arrested the necrotic process and reversed the cutaneous 
pathologic hanges. In a similar case, cyclosporine A (5 
mg/kg) was successfully used to avoid the wound-healing 
problems associated with steroid use. 2 In our case, the use 
of cyclosporine was not an option because of the chronic 
renal failure and pancytopenia. 
The challenging component of our case was the preven- 
tion of sepsis in the setting of pancytopenia with extensive 
open Surgical wounds. Broad-spectrum antibiotic over- 
age, strict isolation, frequent surveillance cultures, and 
pharmacologic stimulation of the bone marrow were 
necessary. Despite these steps, various local infections 
occurred, including dialysis access-related infection and 
upper respiratory tract infection. Fortunately, systemic 
involvement was avoided. 
In conclusion, concurrent pyoderma gangrenosum and 
myeloproiiferative disease represents a unique and challeng- 
ing clinical problem. Early recognition of the skin manifes- 
tations of pyoderma gangrenosum is necessary so that ste- 
roid therapy can be instituted, thereby avoiding radical 
debridement of wounds. The therapy for the associated 
pancytopenia requires support of the bone marrow with 
chemical stimulants. Prophylactic broad-spectrum antibiotic 
coverage is necessary to prevent sepsis. 
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Supraventricular tachyarrhythmia (SVT) , mainly in the 
form of atrial fibrillation (AF), occurs in up to 40% of 
patients undergoing coronary artery bypass grafting 
(CABG) and although usually benign can cause hemody- 
namic instability, prolong hospital stay and increase costs, 
and, rarely, predispose to a cerebrovascular accident. 1 
Pericardial effusions are incriminated in the develop- 
ment of SVT after CABG9 Posterior pericardiotomy has 
recently been reported to reduce the incidence of echo- 
cardiographically defined pericardial effusions from 40% 
in a control group to 8% in a pericardiotomy group with 
